Showing results (21-30 of 64) with videos related to
Sort By:
Pageof 7
European Journal of Biochemistry|February 28, 2003
Functional characterization of Drosophila melanogaster PERK eukaryotic initiation factor 2alpha (eIF2alpha) kinaseNatalia Pomar, Juan J Berlanga, Sonsoles Campuzano, et al.Biopharmaceutics & Drug Disposition|April 5, 2002
Disposition and receptor-site binding of (125)I-EGF after topical administration to skin woundsP A Prats, J Duconge, C Valenzuela, et al.BMC Medicine|November 20, 2020
Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studiesMeghan A Cupp, Margarita Cariolou, Ioanna Tzoulaki, et al.Molecular Endocrinology (Baltimore, Md.)|September 1, 1997
The short form of the prolactin (PRL) receptor silences PRL induction of the beta-casein gene promoterJ J Berlanga, J P Garcia-Ruiz, M Perrot-Applanat, et al.Journal of Neurochemistry|November 18, 2000
Ischemia-induced phosphorylation of initiation factor 2 in differentiated PC12 cells: role for initiation factor 2 phosphataseF Muñoz, M E Martín, J Manso-Tomico, et al.Human Molecular Genetics|March 24, 2017
Identification of genetic variants affecting vitamin D receptor binding and associations with autoimmune diseaseGiuseppe Gallone, Wilfried Haerty, Giulio Disanto, et al.Plos One|December 4, 2009
HIV- 1 protease inhibits Cap- and poly(A)-dependent translation upon eIF4GI and PABP cleavageAlfredo Castelló, David Franco, Pablo Moral-López, et al.Clinical Science (London, England : 1979)|June 9, 1998
Epidermal growth factor protects against carbon tetrachloride-induced hepatic injuryJ Berlanga, M E Caballero, D Ramirez, et al.Antimicrobial Agents and Chemotherapy|September 3, 1999
Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancerJ Carratalà, J Niubó, A Fernández-Sevilla, et al.Bone Marrow Transplantation|August 11, 2001
Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?I Ancín, C Ferrá, D Gallardo, et al.Pageof 7